Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Announces Global Launch of Teriflunomide Making Multiple Sclerosis Therapy More Affordable and Better Available Worldwide","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sclerosis Medicine Teriflunomide in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Epilepsy Medicine Lacosamide in Australia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Antihistamine Bilastine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"OnDosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Agreement Expands Collaboration Between Ondosis and Tiefenbacher Group","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches Generic Versions of The Prostate Cancer Medicines Abiraterone and Abiraterone\/prednisolone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Tiefenbacher Group

    Menu

    Tiefenbacher Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tiefenbacher Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches Generic Versions of The Prostate Cancer Medicines Abiraterone and Abiraterone/prednisolone

              Details:

              Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.

              Lead Product(s): Abiraterone Acetate,Prednisolone

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 17, 2022

              Tiefenbacher Compnay Banner

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              Tiefenbacher Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sclerosis Medicine Teriflunomide in Canada

              Details:

              Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.

              Lead Product(s): Teriflunomide

              Therapeutic Area: Immunology Product Name: Teriflunomide-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2022

              Tiefenbacher Compnay Banner

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              Tiefenbacher Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Epilepsy Medicine Lacosamide in Australia

              Details:

              Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.

              Lead Product(s): Lacosamide

              Therapeutic Area: Neurology Product Name: Lacosamide-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2022

              Tiefenbacher Compnay Banner

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              Tiefenbacher Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Agreement Expands Collaboration Between Ondosis and Tiefenbacher Group

              Details:

              The partnership aims to develop and commercialize products in the intersection between traditional drug-based medicine and digital therapeutics. Another novelty is to dispense the drugs as pellets instead of pills or capsules, making them easier to consume.

              Lead Product(s): Undisclosed

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: OnDosis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration September 26, 2021

              Tiefenbacher Compnay Banner

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              Tiefenbacher Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Antihistamine Bilastine

              Details:

              Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms also a second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis as well as urticaria caused symptoms.

              Lead Product(s): Bilastine

              Therapeutic Area: Immunology Product Name: Bilastine-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2021

              Tiefenbacher Compnay Banner

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              Tiefenbacher Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tiefenbacher Pharmaceuticals Announces Global Launch of Teriflunomide Making Multiple Sclerosis Therapy More Affordable and Better Available Worldwide

              Details:

              Teriflunomide is a novel disease-modifying agent,primarily an inhibitor of dihydroorotate-dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells.

              Lead Product(s): Teriflunomide

              Therapeutic Area: Immunology Product Name: Teriflunomide-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 23, 2021

              Tiefenbacher Compnay Banner

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier
              Tiefenbacher Group
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY